FrancophonIA/ELRC3.0 huggingface dataset:
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vpriv.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Vpriv.
English: The study also looked at control of other signs of the disease such as the increase in the number of platelets in the blood, and the reduction of the size of the liver and spleen.
Croatian: Ispitivanjem je obuhvaćena i kontrola drugih znakova bolesti, kao što je broj trombocita u krvi te smanjenje veličine jetre i slezene.
English: This document is a summary of the European public assessment report (EPAR) for Vpriv.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Vpriv.
English: In one main study involving 35 patients (including 9 children) with type 1 Gaucher disease, Vpriv was compared with imiglucerase (another medicine for Gaucher disease).
Croatian: Vpriv je u okviru jednoga glavnog ispitivanja, u kojem je sudjelovalo 35 bolesnika (uključujući devetero djece) s Gaucherovom bolesti tipa 1, uspoređen s imiglucerazom (drugim lijekom za Gaucherovu bolest).
English: Because the number of patients with Gaucher disease is low, the disease is considered ‘rare', and Vpriv was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 June 2010.
Croatian: Budući da je broj bolesnika s Gaucherovom bolesti nizak, bolest se smatra „rijetkom” te se od 9. lipnja 2010.
English: What is the risk associated with Vpriv?
Croatian: Koji su rizici povezani s lijekom Vpriv?
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Vpriv is available on the Agency's website under EMA website/Find medicine/Human medicines/Rare disease designations.
Croatian: Sažetak mišljenja Odbora za lijekove za rijetke bolesti za lijek Vpriv nalazi se na internetskim stranicama Agencije: EMA website/Find medicine/Human medicines/Rare disease designations.
English: Vpriv is a medicine that contains the active substance velaglucerase alfa.
Croatian: Vpriv je lijek koji sadrži djelatnu tvar velaglucerazu alfa.
English: The study also showed that Vpriv is as effective as imiglucerase in controlling other signs of Gaucher disease.
Croatian: Istraživanje je također pokazalo da je Vpriv učinkovit koliko i imigluceraza u suzbijanju drugih znakova Gaucherove bolesti.
English: Gaucher disease occurs because of the lack of an enzyme called glucocerebrosidase.
Croatian: Do Gaucherove bolesti dolazi zbog nedostatka enzima nazvanog glukocerebrozidaza.
English: What is Vpriv?
Croatian: Što je Vpriv?
English: What is Vpriv used for?
Croatian: Za što se Vpriv koristi?
English: For more information about treatment with Vpriv, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Vpriv pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Vpriv is used for the long-term treatment of patients with Gaucher disease.
Croatian: Vpriv se koristi za dugotrajno liječenje bolesnika s Gaucherovom bolesti.
English: Vpriv is used in patients who have type 1 Gaucher disease, the type that usually affects the liver, spleen and bones.
Croatian: Vpriv se primjenjuje u bolesnika koji boluju od Gaucherove bolesti tipa 1, tipa bolesti koja obično utječe na jetru, slezenu i kosti.
English: Vpriv treatment should be supervised by a doctor experienced in managing patients with Gaucher disease.
Croatian: Liječenje lijekom Vpriv treba nadgledati liječnik s iskustvom u liječenju Gaucherove bolesti.
English: Gaucher disease is a rare inherited disorder, in which people do not have enough of an enzyme called glucocerebrosidase, which normally breaks down a fat called glucocerebroside.
Croatian: Ljudi s Gaucherovom bolesti, rijetkim nasljednim poremećajem, nemaju dovoljno enzima nazvanog glukocerebrozidaza, koji inače razgrađuje masnoću nazvanu glukocerebrozid.
English: The CHMP decided that Vpriv's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) odlučio je da koristi od lijeka Vpriv nadmašuju s njim povezane rizike te je za njega preporučio izdavanje odobrenja za stavljanje u promet.
English: How does Vpriv work?
Croatian: Kako Vpriv djeluje?
English: How is Vpriv used?
Croatian: Kako se Vpriv koristi?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vpriv have also been included in the summary of product characteristics and the package leaflet.
Croatian: U sažetku opisa svojstava lijeka i uputi o lijeku također se nalaze preporuke i mjere opreza za sigurnu i učinkovitu primjenu lijeka Glubrava kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: What benefit has Vpriv shown during the studies?
Croatian: Koje su koristi lijeka Vpriv utvrđene u ispitivanjima?
English: How has Vpriv been studied?
Croatian: Kako je Vpriv ispitivan?
English: During pregnancy:
Croatian: Tijekom trudnoće:
English: Children and adolescents Ontruzant is not recommended for anyone under the age of 18 years.
Croatian: Ontruzant se ne preporučuje osobama mlađima od 18 godina.
English: If this happens to you, contact your doctor immediately.
Croatian: Ako Vam se to dogodi, odmah se obratite liječniku.
English: Unopened vials: 4 years.
Croatian: Neotvorene bočice: 4 godine
English: Therefore your doctor may decide to continue to check your heart functions, even after you finish treatment.
Croatian: Stoga će Vam liječnik možda odlučiti nastaviti kontrolirati srčanu funkciju čak i nakon završetka liječenja.
English: This could be more serious if you are already breathless.
Croatian: Problemi mogu biti još ozbiljniji ako već osjećate nedostatka zraka.
English: Some of these symptoms can be serious and some patients have died (see section 2 under “Warnings and precautions”).
Croatian: Neki od ovih simptoma mogu biti ozbiljni, a neki su bolesnici preminuli (pogledajte dio 2 pod "Upozorenja i mjere opreza").
English: Other medicines and Ontruzant
Croatian: Drugi lijekovi i Ontruzant
English: Before starting the treatment your doctor will determine the amount of HER2 in your tumour.
Croatian: Prije početka liječenja liječnik će Vam odrediti razinu HER2 u tumoru.
English: Study M77001: Full analysis set (intent-to-treat), 24 months results
Croatian: Ispitivanje M77001: potpuni skup analiza (bolesnici predviđeni za liječenje), rezultati nakon 24 mjeseca
English: Monoclonal antibodies attach to specific proteins or antigens.
Croatian: Monoklonska protutijela vežu se za specifične proteine ili antigene.
English: Ontruzant can cause breathing difficulties, especially when it is first given.
Croatian: Ontruzant može izazvati poteškoće u disanju, osobito prilikom prve primjene.
English: • anaphylactic reactions (serious allergic reaction)
Croatian: • anafilaktičke reakcije (ozbiljna alergijska reakcija)
English: • Your doctor will advise you of the risks and benefits of taking Ontruzant during pregnancy.
Croatian: • Liječnik će Vam objasniti rizike i koristi primjene lijeka Ontruzant tijekom trudnoće.
English: If diluted aseptically, it may be stored for 24 hours (do not store above 30°C).
Croatian: Ako je razrijeđena u aseptičkim uvjetima, može se čuvati 24 sata (ne čuvati na temperaturi iznad 30°C).
English: What Ontruzant looks like and contents of the pack
Croatian: Kako Ontruzant izgleda i sadržaj pakiranja
English: The presence of trastuzumab in the serum of infant monkeys was not associated with any adverse effects on their growth or development from birth to 1 month of age.
Croatian: Prisutnost trastuzumaba u serumu majmunčadi nije bila povezana sa štetnim učincima na rast i razvoj od rođenja do 1 mjeseca života.
English: These events may occur as part of an infusion-related reaction or with a delayed onset.
Croatian: Ti se događaji mogu pojaviti kao dio reakcije povezane s infuzijom ili s odgođenim nastupom.
English: Ontruzant may also be given once a week for metastatic breast cancer.
Croatian: Ontruzant se također može davati jednom tjedno za metastatski rak dojke.
English: Contents of the pack and other information What Ontruzant contains
Croatian: Sadržaj pakiranja i druge informacije Što Ontruzant sadrži
English: The t1/2 decreases with decreasing concentrations within a dosing interval (see Table 16).
Croatian: Poluvijek (t1/2) smanjuje se s padom koncentracija unutar jednog intervala doziranja (vidjeti tablicu 16).
English: Ontruzant is given as an infusion into a vein (intravenous infusion, “drip”).
Croatian: Ontruzant se primjenjuje infuzijom izravno u venu (intravenska infuzija, „drip“).
English: Ontruzant may affect your ability to drive a car or operate machines.
Croatian: Ontruzant može utjecati na sposobnost upravljanja vozilima ili rada sa strojevima.
English: Some of these side effects may be serious and may lead to hospitalisation.
Croatian: Neke od tih nuspojava mogu biti ozbiljne i zahtijevati bolničko liječenje.
English: HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth.
Croatian: HER2 se u velikim količinama nalazi na površini nekih stanica raka te potiče njihov rast.
English: The dose of Ontruzant depends on your body weight.
Croatian: Potrebna doza lijeka Ontruzant ovisi o Vašoj tjelesnoj težini.
English: AUC0-21days
Croatian: AUC0-21 dan
English: If you develop any signs of heart failure (inadequate pumping of blood by the heart), your heart function may be checked more frequently (every six to eight weeks), you may receive treatment for heart failure or you may have to stop Ontruzant treatment.
Croatian: Ako se pojave znakovi zatajenja srca (srce nedostatno pumpa krv), možda ćete srčanu funkciju kontrolirati češće (svakih šest do osam tjedana), a možda ćete primati terapiju za zatajenje srca ili ćete morati prekinuti liječenje lijekom Ontruzant.
English: The product is not intended to be stored after reconstitution and dilution unless this has taken place under controlled and validated aseptic conditions.
Croatian: Čuvanje lijeka nakon rekonstitucije i razrjeđivanja nije predviđeno, osim ako je ono obavljeno u kontroliranim i validiranim aseptičkim uvjetima.
English: If you stop using Ontruzant
Croatian: Ako prestanete primati Ontruzant
English: Do not stop using this medicine without talking to your doctor first.
Croatian: Nemojte prestati primati Ontruzant ako o tome prethodno niste razgovarali sa svojim liječnikom.
English: The efficacy results from the BCIRG 006 are summarized in Tables 9 and 10.
Croatian: Rezultati djelotvornosti iz ispitivanja BCIRG 006 sažeto su prikazani u tablicama 9 i 10.
English: If you receive Ontruzant in combination with chemotherapy, some of them may also be due to the chemotherapy.
Croatian: Ako primate Ontruzant u kombinaciji s kemoterapijom, neke od njih mogu biti i posljedica primljene kemoterapije.
English: AUCss, 0-21 days
Croatian: AUCss, 0-21 dan
English: Caution should be exercised for pneumonitis, especially in patients being treated concomitantly with taxanes.
Croatian: Potreban je oprez u slučaju pneumonitisa, osobito u bolesnika koji istodobno primaju taksane.
English: Observation N=1697***
Croatian: Opservacija N=1697***
English: 1 Denotes adverse reactions that are reported largely in association with Infusion-related reactions.
Croatian: 1 Označava nuspojave koje su uglavnom prijavljivane u vezi s reakcijama povezanima s infuzijom.
English: If a pregnant woman is treated with trastuzumab, or if a patient becomes pregnant while receiving trastuzumab or within 7 months following the last dose of trastuzumab, close monitoring by a multidisciplinary team is desirable.
Croatian: Ako se trudnicu liječi trastuzumabom ili ako bolesnica zatrudni tijekom liječenja trastuzumabom ili unutar 7 mjeseci nakon posljednje doze trastuzumaba, poželjno je pažljivo multidisciplinarno praćenje.
English: As animal reproduction studies are not always predictive of human response, trastuzumab should be avoided during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus.
Croatian: Budući da se na temelju ispitivanja provedenih na životinjama ne može pouzdano predvidjeti odgovor kod ljudi, primjenu trastuzumaba u trudnoći treba izbjegavati osim ako je moguća korist za majku veća od mogućeg rizika za fetus.
English: Greater than 70% of patients enrolled exhibited 3+ overexpression.
Croatian: Više od 70% uključenih bolesnika imalo je povećanu ekspresiju razine 3+.
English: These medicines (or any other anthracyclines) can damage heart muscle and increase the risk of heart problems with Ontruzant.
Croatian: Ti lijekovi (ili neki drugi antraciklini) mogu oštetiti srčani mišić i povećati rizik od srčanih problema pri primjeni lijeka Ontruzant.
English: Store in a refrigerator (2°C - 8°C).
Croatian: Čuvati u hladnjaku (2ºC - 8ºC).
English: For monotherapy, the rate was 6%-9%.
Croatian: Kod primjene u monoterapiji, stopa je iznosila 6% do 9%.
English: Chemo + trastuzumab (n=115)
Croatian: Kemoterapija + trastuzumab (n=115)
English: Patients who develop asymptomatic cardiac dysfunction may benefit from more frequent monitoring (e.g. every 6-8 weeks).
Croatian: Bolesnicima koji razviju asimptomatsku disfunkciju srca mogli bi pomoći češći pregledi (primjerice, svakih 6-8 tjedana).
English: Ontruzant should only be given by a doctor or nurse.
Croatian: Ontruzant smije primijeniti samo liječnik ili medicinska sestra.
English: Taking into account the PRAC Assessment Report on the PSUR(s) for trastuzumab, the scientific conclusions of the CHMP are as follows:
Croatian: Uzimajući u obzir PRAC-ovo izvješće o ocjeni periodičkog(ih) izvješća o neškodljivosti lijeka (PSUR) za trastuzumab, znanstveni zaključci CHMP-a su sljedeći:
English: Treatment with Ontruzant (alone or with a taxane) may affect the heart, especially if you have ever used an anthracycline (taxanes and anthracyclines are two other kinds of medicine used to treat cancer).
Croatian: Liječenje lijekom Ontruzant (samim ili u kombinaciji s taksanom) može utjecati na srce, osobito ako ste nekada već uzimali antracikline (taksani i antraciklini su druge dvije vrste lijekova koji se koriste za liječenje raka).
English: Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Croatian: Unutar svake skupine učestalosti, nuspojave su prikazane prema sve manjoj ozbiljnosti.
English: Patients should be observed for at least six hours after the start of the first infusion and for two hours after the start of the subsequent infusions for symptoms like fever and chills or other infusion-related symptoms (see sections 4.4 and 4.8).
Croatian: Bolesnike je potrebno promatrati najmanje šest sati nakon početka prve infuzije te dva sata nakon početka svake sljedeće infuzije kako bi se uočili simptomi poput vrućice i zimice ili drugi simptomi povezani s primjenom infuzije (vidjeti dio 4.4 i 4.8).
English: It may take up to 7 months for Ontruzant to be removed from the body.
Croatian: Može biti potrebno i do 7 mjeseci da se Ontruzant ukloni iz tijela.
English: • swelling or bleeding at the back of the eyes
Croatian: • oticanje ili krvarenje u pozadini oka • šok
English: Trastuzumab 1 Year N=1702***
Croatian: Trastuzumab tijekom 1 godine N=1702***
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 15 November 2017
Croatian: Datum prvog odobrenja: 15. studeni 2017.
English: When Ontruzant binds to HER2 it stops the growth of such cells and causes them to die.
Croatian: Kada se Ontruzant veže na HER2, zaustavlja rast tih stanica i uzrokuje njihovo odumiranje.
English: If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab.
Croatian: Ako je moguće, liječnici bi trebali izbjegavati primjenu antraciklinske terapije do 7 mjeseci nakon prestanka primjene trastuzumaba.
English: Your doctor may prescribe Ontruzant for the treatment of breast and gastric cancer when:
Croatian: Liječnik Vam može propisati Ontruzant za liječenje raka dojke i želuca ako:
English: After reconstitution with sterile water for injection the reconstituted solution is physically and chemically stable for 48 hours at 2°C-8°C.
Croatian: Nakon rekonstitucije sa sterilnom vodom za injekcije rekonstituirana otopina je fizički i kemijski stabilna 48 sati na temperaturi 2°C-8°C.
English: As human IgG1 is secreted into human milk, and the potential for harm to the infant is unknown, women should not breast-feed during trastuzumab therapy and for 7 months after the last dose.
Croatian: Budući da se humani IgG1 izlučuje u majčino mlijeko, a nema saznanja o mogućem štetnom učinku na novorođenče, žene ne smiju dojiti tijekom liječenja trastuzumabom ni 7 mjeseci nakon posljednje doze lijeka.
English: Other side effects that have been reported with Ontruzant use (frequency cannot be estimated from the available data):
Croatian: Ostale nuspojave koje su uočene pri primjeni lijeka Ontruzant (učestalost se ne može procijeniti iz dostupnih podataka):
English: No incompatibilities between Ontruzant and polyvinylchloride, polyethylene or polypropylene bags have been observed.
Croatian: Nisu primijećene inkompatibilnosti između lijeka Ontruzant i polivinilkloridnih, polietilenskih ili polipropilenskih vrećica.
English: following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1).
Croatian: nakon kirurškog zahvata, kemoterapije (neoadjuvantne ili adjuvantne) i radioterapije (ako su provedeni) (vidjeti dio 5.1)
English: FP + H: fluoropyrimidine/cisplatin + trastuzumab FP: fluoropyrimidine/cisplatin a Odds ratio
Croatian: FP + H: fluoropirimidin/cisplatin + trastuzumab FP: fluoropirimidin/cisplatin a omjer izgleda
English: Trastuzumab 1 Year N=1693
Croatian: Trastuzumab tijekom 1 godine N=1693
English: All the terms included are based on the highest percentage seen in pivotal clinical trials.
Croatian: Sve uključene nuspojave temelje se na najvišim postotcima zabilježenim u ključnim kliničkim ispitivanjima.
English: Fertility There is no fertility data available.
Croatian: Nema dostupnih podataka o plodnosti.
English: The bioactivity of D7D and the clinical impact of the elevation of this metabolite was unclear.
Croatian: D7D niti klinički utjecaj povećanih koncentracija toga metabolita.
English: Clinically significant interactions between trastuzumab and the concomitant medicinal products used in clinical trials have not been observed.
Croatian: Nisu primijećene klinički značajne interakcije između trastuzumaba i istodobno primijenjenih lijekova koji su se primjenjivali u kliničkim ispitivanjima.
English: EU/1/17/1241/001 EU/1/17/1241/002
Croatian: EU/1/17/1241/002
English: 1Blood pressure increased
Croatian: 1povišeni krvni tlak
English: On very rare occasions, patients have experienced the onset of infusion symptoms and pulmonary symptoms more than six hours after the start of the trastuzumab infusion.
Croatian: U vrlo rijetkim slučajevima, simptomi reakcije povezane s infuzijom i plućni simptomi pojavili su se nakon više od šest sati od početka infuzije trastuzumaba.
English: Placental transfer of trastuzumab during the early (days 20-50 of gestation) and late (days 120-150 of gestation) fetal development period was observed.
Croatian: Primijećeno je da trastuzumab prolazi kroz posteljicu za vrijeme ranog (od 20. do 50. dana gestacije) i kasnog (od 120. do 150. dana gestacije) razdoblja fetalnog razvoja.
English: The majority of patients with cardiac symptoms and evidence of a clinical benefit of trastuzumab treatment continued on therapy without additional clinical cardiac events.
Croatian: Većina bolesnika sa simptomima srčane bolesti i dokazanom kliničkom koristi liječenja trastuzumabom, nastavila je s terapijom bez dodatnih kliničkih srčanih događaja.
English: Paediatric population There is no relevant use of Ontruzant in the paediatric population.
Croatian: Pedijatrijska populacija Nema relevantne primjene lijeka Ontruzant u pedijatrijskoj populaciji.
English: There was a correlation between shed antigen and SGOT/AST levels; part of the impact of shed antigen on clearance may have been explained by SGOT/AST levels.
Croatian: Postojala je korelacija između odcijepljenog antigena i razina vriijednosti SGOT/AST; dio utjecaja odcijepljenog antigena na klirens možda bi se mogao objasniti razinama vrijednosti SGOT/AST.
English: In patients who receive anthracycline-containing chemotherapy further monitoring is recommended, and should occur yearly up to 5 years from the last administration of trastuzumab, or longer if a continuous decrease of LVEF is observed.
Croatian: U bolesnika koji primaju kemoterapiju koja sadrži antracikline, preporučuje se daljnje praćenje jednom godišnje do 5 godina od posljednje primjene trastuzumaba ili dulje ako je uočeno daljnje smanjenje LVEF-a.
English: Reversibility of severe CHF (defined as a sequence of at least two consecutive LVEF values ≥50% after the event) was evident for 71.4% of trastuzumab-treated patients.
Croatian: Reverzibilnost teškog kongestivnog zatajenja srca (definirana kao slijed najmanje dviju uzastopnih vrijednosti LVEF ≥50% nakon događaja) bila je primjetna u 71,4% bolesnika liječenih trastuzumabom.
English: To ensure accurate and reproducible results, the testing must be performed in a specialised laboratory, which can ensure validation of the testing procedures.
Croatian: Da bi se dobili točni i ponovljivi rezultati, testiranje se mora provesti u specijaliziranom laboratoriju koji može osigurati primjenu validiranih postupaka ispitivanja.
English: Patients were treated with trastuzumab until progression of disease.
Croatian: Bolesnici su primali trastuzumab sve do progresije bolesti.
English: The exploratory analyses of covariates with information in only a subset of patients suggested that patients with greater shed HER2-ECD level had faster nonlinear clearance (lower Km) (P<0.001).
Croatian: Eksplorativne analize kovarijanti na temelju podataka prikupljenih samo u jednoj podskupini bolesnika pokazali su da su bolesnici s višom razinom odcjepljivanja HER2-ECD-a imali brži nelinearni klirens (niži Km) (P<0,001).
English: Talk to your doctor, pharmacist or nurse before you are given Ontruzant if:
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primite Ontruzant:
English: Ontruzant is for intravenous use.
Croatian: Ontruzant je za intravensku primjenu.
English: This investigative clinical trial assay performed in a central laboratory utilised a 0 to 3+ scale.
Croatian: Ovaj istraživački test za klinička ispitivanja proveden je u središnjem laboratoriju, a rezultat je procjenjivan ljestvicom od 0 do 3+.
English: Accurate and validated assay methods should be used (see sections 4.4 and 5.1).
Croatian: Treba koristiti točne i validirane metode određivanja (vidjeti dijelove 4.4 i
English: Occasionally, symptoms start later than six hours after the infusion begins.
Croatian: Simptomi ponekad mogu početi i više od šest sati nakon početka infuzije.
English: In order to prevent medication errors it is important to check the vial labels to ensure that the medicine being prepared and given is Ontruzant (trastuzumab) and not trastuzumab emtansine.
Croatian: U svrhu sprječavanja medikacijskih pogrešaka, važno je provjeriti naljepnice na bočicama kako biste bili sigurni da je lijek koji se priprema i primjenjuje Ontruzant (trastuzumab), a ne trastuzumab emtanzin.
English: Details of risk minimisation measures that are consistent with the EU Risk Management Plan are presented in (section 4.4) Warnings and Precautions.
Croatian: Pojedinosti o mjerama minimizacije rizika u skladu s Europskim planom upravljanja rizikom navedene su u dijelu Posebna upozorenja i mjere opreza pri uporabi (dio 4.4).
English: Total CL range from Cmax,ss to Cmin,ss
Croatian: Raspon ukupnog klirensa od Cmax,ss do Cmin,ss